var data={"title":"Primary drugs in pediatric resuscitation","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Primary drugs in pediatric resuscitation</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/contributors\" class=\"contributor contributor_credentials\">Mark E Ralston, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/contributors\" class=\"contributor contributor_credentials\">Susan B Torrey, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/contributors\" class=\"contributor contributor_credentials\">James F Wiley, II, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 10, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary drugs used for pediatric resuscitation are reviewed here.</p><p>Pediatric basic life support, pediatric advanced life support, and the use of <a href=\"topic.htm?path=naloxone-pediatric-drug-information\" class=\"drug drug_pediatric\">naloxone</a> in children with opioid intoxication are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pediatric-basic-life-support-for-health-care-providers\" class=\"medical medical_review\">&quot;Pediatric basic life support for health care providers&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pediatric-advanced-life-support-pals\" class=\"medical medical_review\">&quot;Pediatric advanced life support (PALS)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=opioid-intoxication-in-children-and-adolescents#H27\" class=\"medical medical_review\">&quot;Opioid intoxication in children and adolescents&quot;, section on 'Naloxone'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H5952713\"><span class=\"h1\">DRUG THERAPY BY CLINICAL CONDITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary drugs used in pediatric advanced life support (PALS) and pediatric resuscitation according to clinical presentation are as follows (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>] (see <a href=\"topic.htm?path=pediatric-advanced-life-support-pals\" class=\"medical medical_review\">&quot;Pediatric advanced life support (PALS)&quot;</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hypoxemia</strong> &ndash; Oxygen</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hypoglycemia</strong> &ndash; Glucose</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Asystole or pulseless electrical activity</strong> &ndash; Oxygen, <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> (<a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pulseless with a shockable rhythm (VF, pulseless ventricular tachycardia [pVT], or torsades de pointes [TdP])</strong> &ndash; Oxygen, <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a>, and, for VF and pVT, <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">lidocaine</a> or <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a>, and for TdP, <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">magnesium sulfate</a> as adjuncts to high quality cardiopulmonary resuscitation and defibrillation (<a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Uncomplicated supraventricular tachycardia (SVT)</strong> &ndash; Oxygen, <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> (<a href=\"image.htm?imageKey=EM%2F67438\" class=\"graphic graphic_algorithm graphicRef67438 \">algorithm 1</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Possible ventricular tachycardia or aberrant SVT</strong> &ndash; Oxygen, <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a>, <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a>, <a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">procainamide</a> (<a href=\"image.htm?imageKey=EM%2F67438\" class=\"graphic graphic_algorithm graphicRef67438 \">algorithm 1</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hypomagnesemia or TdP</strong> &ndash; <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">Magnesium sulfate</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bradycardia</strong> &ndash; Oxygen, <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a>, <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> (<a href=\"image.htm?imageKey=EM%2F52446\" class=\"graphic graphic_algorithm graphicRef52446 \">algorithm 2</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Severe metabolic acidosis associated with prolonged cardiac arrest or shock</strong> &ndash; <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">Sodium bicarbonate</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hypocalcemia, hypermagnesemia, hyperkalemia or calcium channel blocker overdose</strong> &ndash; <a href=\"topic.htm?path=calcium-chloride-pediatric-drug-information\" class=\"drug drug_pediatric\">Calcium chloride</a></p><p/><p>The use of <a href=\"topic.htm?path=naloxone-pediatric-drug-information\" class=\"drug drug_pediatric\">naloxone</a> for children with suspected opioid intoxication and clinical findings of coma, depressed respirations, <span class=\"nowrap\">and/or</span> miosis is discussed separately. (See <a href=\"topic.htm?path=opioid-intoxication-in-children-and-adolescents#H27\" class=\"medical medical_review\">&quot;Opioid intoxication in children and adolescents&quot;, section on 'Naloxone'</a>.)</p><p>In children undergoing pediatric advanced life support (PALS), medications are of secondary importance to the prompt treatment of hypoxemia and respiratory impairment, initiation of high quality cardiopulmonary resuscitation in pulseless patients, and early defibrillation in patients with ventricular arrhythmias (ventricular fibrillation [VF], pulseless ventricular tachycardia [pVT], or pulseless torsade de pointes [TdP]). (See <a href=\"topic.htm?path=pediatric-basic-life-support-for-health-care-providers#H4\" class=\"medical medical_review\">&quot;Pediatric basic life support for health care providers&quot;, section on 'Basic life support algorithms'</a> and <a href=\"topic.htm?path=pediatric-advanced-life-support-pals\" class=\"medical medical_review\">&quot;Pediatric advanced life support (PALS)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4897046\"><span class=\"h1\">SUBSTRATE DELIVERY</span></p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Oxygen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The fundamental goal of basic and advanced life support is to support cerebral, myocardial, and systemic oxygenation before irreversible injury occurs. Because respiratory compromise is the leading cause of cardiac arrests in children, 100 percent oxygen should be administered, to any child who is suspected of being hypoxemic using an appropriate delivery device. The potential negative effects of high concentrations of oxygen are not a consideration in the setting of cardiopulmonary arrest. (See <a href=\"topic.htm?path=continuous-oxygen-delivery-systems-for-infants-children-and-adults\" class=\"medical medical_review\">&quot;Continuous oxygen delivery systems for infants, children, and adults&quot;</a> and <a href=\"topic.htm?path=oxygen-toxicity\" class=\"medical medical_review\">&quot;Oxygen toxicity&quot;</a>.)</p><p>However, in perfusing patients and those who were in arrest but regained spontaneous circulation, oxygen therapy should be titrated to maintain PaO<sub>2 </sub>between 60 and 300 mmHg or pulse oximetry of 94 to 99 percent to avoid oxygen toxicity. (See <a href=\"topic.htm?path=pediatric-advanced-life-support-pals#H289869188\" class=\"medical medical_review\">&quot;Pediatric advanced life support (PALS)&quot;, section on 'Avoid low and high arterial oxygen'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Glucose (dextrose)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypoglycemia may accompany trauma, respiratory failure, shock, sepsis, and many other illnesses that result in cardiopulmonary arrest. Small infants are particularly prone to developing hypoglycemia because of inadequate glycogen stores. In addition, acute illness may have caused decreased caloric intake or excessive losses (eg, from diarrhea and vomiting).</p><p>A rapid bedside glucose test should be performed in all pediatric patients who are clinically unstable because the clinical signs of hypoglycemia and hypoxemia are similar (eg, altered mental status, poor perfusion, tachycardia, and hypotension). (See <a href=\"topic.htm?path=approach-to-hypoglycemia-in-infants-and-children\" class=\"medical medical_review\">&quot;Approach to hypoglycemia in infants and children&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; Glucose is the primary metabolic substrate for the neonatal myocardium, and hypoglycemia may contribute to myocardial dysfunction [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>]. Glucose also is a significant energy source in older infants and children during periods of ischemia [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>]. Whether glucose administration improves cardiac function or survival in hypoglycemic children with cardiac arrest is not known [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and contraindications </strong>&ndash; During pediatric resuscitation, patients with a low bedside glucose (&lt; 60 <span class=\"nowrap\">mg/dL</span> [3.3 <span class=\"nowrap\">mmol/L])</span> warrant treatment, but routine administration of glucose without evaluation of the serum glucose is <strong>not</strong> recommended [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>]. Empiric treatment with glucose may be appropriate if bedside glucose determination is <strong>not</strong> available and the infant or child has symptoms of hypoglycemia or is at risk for developing hypoglycemia. Symptomatic patients with a bedside glucose between 60 and 70 <span class=\"nowrap\">mg/dL</span> [3.89 <span class=\"nowrap\">mmol/L]</span> may also warrant treatment especially if they have a condition such as diabetes mellitus which has led to habituation to a higher than normal baseline blood glucose. (See <a href=\"topic.htm?path=approach-to-hypoglycemia-in-infants-and-children\" class=\"medical medical_review\">&quot;Approach to hypoglycemia in infants and children&quot;</a>.) </p><p/><p class=\"bulletIndent1\">The routine administration of glucose during pediatric resuscitation is <strong>not</strong> recommended because of the absence of data demonstrating benefit and the potential harm of hyperglycemia. Large volumes of dextrose-containing fluids should not be given to normoglycemic children during resuscitation because they can cause hyperglycemia, which can induce osmotic diuresis, produce or aggravate hypokalemia, or worsen ischemic brain injury [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2-5\" class=\"abstract_t\">2-5</a>]. Evidence for the harm of empiric glucose administration is less convincing for neonates. As an example, in a newborn animal model, administration of glucose improved survival in hypoxic rat pups and did not increase the extent of hypoxic-ischemic brain damage [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration</strong> &ndash; The dose of glucose recommended by the Pediatric Life Support Course is 0.5 to 1 <span class=\"nowrap\">g/kg</span> [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>] although others have suggested a lower dose of 0.25 <span class=\"nowrap\">g/kg</span> to avoid unintentional osmotic diuresis. (See <a href=\"topic.htm?path=approach-to-hypoglycemia-in-infants-and-children#H12\" class=\"medical medical_review\">&quot;Approach to hypoglycemia in infants and children&quot;, section on 'Treatment'</a>.)</p><p/><p class=\"bulletIndent1\">It should be administered via intravenous (IV) or intraosseous (IO) infusion. The maximum concentration of glucose that can be administered through a peripheral vein is 25 percent dextrose in water (D25W); higher concentrations cause sclerosis of peripheral veins. Thus, 50 percent solutions of dextrose in water (D50W) must be diluted 1:1 with sterile water before peripheral administration in children. However, in infants and children younger than five years of age, 10 percent dextrose in water is typically used.</p><p/><p class=\"bulletIndent1\">The volume of solution necessary to achieve the desired dose varies depending upon the dextrose concentration of the solution. Each of the following alternatives provides 0.5 to 1 <span class=\"nowrap\">g/kg</span> of glucose [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>2 to 4 <span class=\"nowrap\">mL/kg</span> of D25W</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>5 to 10 <span class=\"nowrap\">mL/kg</span> of 10 percent dextrose in water (D10W)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A bolus of 10 to 20 <span class=\"nowrap\">mL/kg</span> of 5 percent dextrose in normal saline or lactated Ringer's solution</p><p/><p class=\"bulletIndent1\">Children with hypoglycemia due to a sulfonylurea overdose may especially warrant this higher initial dose of glucose. (See <a href=\"topic.htm?path=sulfonylurea-agent-poisoning#H7\" class=\"medical medical_review\">&quot;Sulfonylurea agent poisoning&quot;, section on 'Hypoglycemia'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4897086\"><span class=\"h1\">CARDIAC ARREST (ASYSTOLE OR PULSELESS ELECTRICAL ACTIVITY)</span></p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Epinephrine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Administration of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> is the intervention most likely to be of benefit when basic life support and volume resuscitation do not restore effective circulation (<a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>) (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/7,8\" class=\"abstract_t\">7,8</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; The actions of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> include both alpha- and beta-adrenergic stimulation.</p><p/><p class=\"bulletIndent1\">The alpha-mediated peripheral arterial vasoconstriction is the beneficial action of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> in cardiac arrest. Peripheral arterial vasoconstriction elevates systemic vascular resistance, thereby increasing the aortic-right atrial pressure gradient during the decompression phase of cardiopulmonary resuscitation (CPR). This gradient, also called the coronary perfusion pressure, correlates directly with myocardial blood flow in animal models, and is a good predictor of return of spontaneous circulation (ROSC) in animals and humans [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/9-11\" class=\"abstract_t\">9-11</a>].</p><p/><p class=\"bulletIndent1\">In addition, increased systemic vascular tone raises the arterial pressure during the compression phase of CPR, thereby raising the cerebral perfusion pressure [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/12\" class=\"abstract_t\">12</a>].</p><p/><p class=\"bulletIndent1\">Thus, the administration of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> increases blood flow to both the heart and the brain. Additional alpha-adrenergic vasoconstrictor effects of epinephrine include reduced blood flow to the splanchnic, renal, mucosal, and dermal vascular beds [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\">Beta-adrenergic stimulation increases myocardial contractility and heart rate and relaxes smooth muscle in the coronary arteries, cerebral arteries, skeletal muscle vascular beds, and bronchi [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2,13\" class=\"abstract_t\">2,13</a>]. Other effects of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> include stimulation of spontaneous cardiac contraction in asystole and enhanced ability to terminate ventricular fibrillation by electrical defibrillation [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and contraindications</strong> &ndash; <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">Epinephrine</a> is indicated for the treatment of cardiac arrest, symptomatic bradycardia not responsive to oxygen and ventilation, and hypotension not responsive to fluid administration [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>]. Asystole and bradyarrhythmias are the most common rhythms in pediatric cardiac arrests [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>]. The administration of epinephrine to children with these rhythms may generate a perfusing pressure [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/15\" class=\"abstract_t\">15</a>]. In addition, the use of epinephrine in children with ventricular fibrillation, an uncommon rhythm in pediatric arrest, may render the rhythm more susceptible to electrical defibrillation [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/9\" class=\"abstract_t\">9</a>].</p><p/><p class=\"bulletIndent1\">Contraindications to the use of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> are rare in children and consist of:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hypersensitivity to <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> or one of its components &ndash; Although evidence is lacking for its use as the initial drug for pediatric arrest, <a href=\"topic.htm?path=vasopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">vasopressin</a> is a possible alternative to epinephrine in patients with cardiac arrest. Children with bradycardia and hemodynamic compromise can be given <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> and, if necessary, undergo transthoracic or transvenous pacing. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Narrow angle glaucoma &ndash; The&nbsp;risk of worsening narrow angle glaucoma will rarely outweigh the benefit for children in cardiac arrest with this uncommon condition. The clinician should weigh the harm of worsening narrow angle glaucoma with the benefit of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> administration in children with cardiac arrest, in those rare instances in which a patient is known to carry this diagnosis. For children with bradycardia and cardiac compromise, <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> and, if necessary, transthoracic or intravenous pacing may attempted rather than giving epinephrine. &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration</strong> &ndash; The dose of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> varies depending on the route of administration. Although it can be given endotracheally, the intravenous (IV) or intraosseous (IO) route is preferred [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. Epinephrine should be administered through a secure intravascular line because infiltration into the tissues may cause local ischemia, which may lead to tissue injury and ulceration [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/15\" class=\"abstract_t\">15</a>]. Epinephrine is inactivated by alkaline solutions and should not be added to solutions containing <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a>. To help prevent medication errors, ratio expressions have been removed from epinephrine labels in the United States [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/16\" class=\"abstract_t\">16</a>]. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, <strong>the 0.1 <span class=\"nowrap\">mg/mL</span> concentration of epinephrine may be labeled as 1:10,000 and the 1 <span class=\"nowrap\">mg/mL</span> concentration may be labeled as 1:1000</strong>. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Parenteral </strong>&ndash; The IV or IO dose of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> is 0.01 <span class=\"nowrap\">mg/kg</span> given as 0.1 <span class=\"nowrap\">mL/kg</span> of the 0.1 <span class=\"nowrap\">mg/mL</span> solution. Repeated doses may be given every three to five minutes as needed [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Endotracheal </strong>&ndash; The recommended dose of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> when given by the endotracheal route is 0.1 <span class=\"nowrap\">mg/kg</span> given as 0.1 <span class=\"nowrap\">mL/kg</span> of the 1 <span class=\"nowrap\">mg/mL</span> solution, which can also be repeated every three to five minutes as needed [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. The endotracheal dosing of epinephrine in neonates is discussed separately. (See <a href=\"topic.htm?path=neonatal-resuscitation-in-the-delivery-room#H24\" class=\"medical medical_review\">&quot;Neonatal resuscitation in the delivery room&quot;, section on 'Epinephrine'</a>.)</p><p/><p class=\"bulletIndent2\">Higher doses of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> are required for endotracheal administration because peak levels achieved via this route are less than 10 percent of those achieved with IV administration [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/17\" class=\"abstract_t\">17</a>]. In addition, studies in animals using endotracheal epinephrine at doses of 0.01 to 0.02 <span class=\"nowrap\">mg/kg</span> demonstrated no discernible effect on systolic or diastolic blood pressure [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/18\" class=\"abstract_t\">18</a>].</p><p/><p class=\"bulletIndent2\">Optimal endotracheal drug absorption depends upon delivery of the drug as deeply as possible into the airway [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/19\" class=\"abstract_t\">19</a>]. Administration of medications endotracheally is discussed below. (See <a href=\"#H23863422\" class=\"local\">'Endotracheal drug administration'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>High-dose </strong><a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a><strong> </strong>&ndash; High-dose epinephrine (HDE) is no longer recommended for use in pediatric resuscitation [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. </p><p/><p class=\"bulletIndent2\">HDE (0.1 to 0.2 <span class=\"nowrap\">mg/kg)</span> had been previously recommended for second and subsequent doses for infants and children with unresponsive asystole or pulseless electrical activity (PEA) on the basis of animal and adult studies that demonstrated improved cerebral and cardiac perfusion with higher doses of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/15,20-22\" class=\"abstract_t\">15,20-22</a>]. In addition, several studies reported an increase in return of spontaneous circulation in children who received HDE after failing to respond to two standard doses (SDE) [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/10,23\" class=\"abstract_t\">10,23</a>].</p><p/><p class=\"bulletIndent2\">However, subsequent large, multi-institutional, adult trials, well controlled animal outcome studies, and retrospective pediatric reviews failed to show any benefit of HDE in terms of survival to discharge and neurologic outcome [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/24-28\" class=\"abstract_t\">24-28</a>]. Finally, a controlled trial evaluated children with in-hospital cardiac arrest who were randomly assigned to receive HDE or SDE after failure of an initial dose of SDE [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/29\" class=\"abstract_t\">29</a>]. Although return of spontaneous circulation was similar in both groups, HDE was associated with increased risk of death (adjusted odds ratio [OR] 7.9, 95% CI 0.9-72.5).</p><p/><p class=\"bulletIndent2\">HDE is also not indicated for symptomatic bradycardia unresponsive to oxygen and ventilation <span class=\"nowrap\">and/or</span> hypotension unresponsive to fluid therapy [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2,13,19\" class=\"abstract_t\">2,13,19</a>]. In these situations, a continuous <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> infusion should be administered. (See <a href=\"topic.htm?path=systemic-inflammatory-response-syndrome-sirs-and-sepsis-in-children-definitions-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=hypovolemic-shock-in-children-initial-evaluation-and-management#H13\" class=\"medical medical_review\">&quot;Hypovolemic shock in children: Initial evaluation and management&quot;, section on 'Fluid resuscitation'</a>.)</p><p/><p class=\"bulletIndent1\">Despite the recognized benefits of increasing coronary and cerebral perfusion pressures, evidence has shown a negative safety profile of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a>, due to its ability to increase myocardial workload, decrease subendocardial perfusion, and induce ventricular arrhythmias [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/30\" class=\"abstract_t\">30</a>]. Most of the evidence on the toxicity of epinephrine has been described in hemodynamically intact animals and adults. Whether these results can be applied to the low flow state present during cardiac arrest is not clear [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/10,19\" class=\"abstract_t\">10,19</a>]. Very high doses of epinephrine have been associated with a pattern of myocardial injury called &quot;contraction band necrosis&quot; [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/31\" class=\"abstract_t\">31</a>]. Damage to the arterial vascular endothelium also may occur [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/32\" class=\"abstract_t\">32</a>]. One study found that adult patients receiving more than 15 mg cumulative-dose epinephrine had an increased mortality rate at 24 hours after arrest compared with patients receiving less than 15 mg [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=vasopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">Vasopressin</a><strong> versus </strong><a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a><strong> for pulseless arrest</strong> &ndash; Vasopressin, a nonadrenergic endogenous peptide that induces peripheral, coronary, and renal vasoconstriction via stimulation of Vasopression1 receptors, lacks the adverse effects of epinephrine and has gained much attention as a replacement vasopressor [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/34\" class=\"abstract_t\">34</a>]. Another possible advantage of vasopressin is that Vasopressin2 receptor stimulation induces vasodilation and may lessen the end-organ hypoperfusion thought to occur with epinephrine [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p class=\"bulletIndent1\">Small pediatric case series suggest that <a href=\"topic.htm?path=vasopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">vasopressin</a>, or its long-acting analog, terlipressin, may be effective in refractory cardiac arrest when standard therapy fails [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/36-38\" class=\"abstract_t\">36-38</a>]. These reports include patients with prolonged return of spontaneous circulation (ROSC) and intact neurologic survival. However, a large National Registry of Cardiopulmonary Resuscitation (NRCPR) retrospective observational study found that vasopressin was associated with a lower frequency of ROSC, and a trend toward lower 24-hour and discharge survival [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/39\" class=\"abstract_t\">39</a>]. Thus, vasopressin is not included in the consensus pediatric cardiac arrest algorithm (<a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>).</p><p/><p class=\"bulletIndent1\">The use of <a href=\"topic.htm?path=vasopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">vasopressin</a> in adult resuscitation is discussed separately. (See <a href=\"topic.htm?path=supportive-data-for-advanced-cardiac-life-support-in-adults-with-sudden-cardiac-arrest#H18\" class=\"medical medical_review\">&quot;Supportive data for advanced cardiac life support in adults with sudden cardiac arrest&quot;, section on 'Vasopressin'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4897154\"><span class=\"h1\">TACHYARRHYTHMIAS AND CARDIAC ARREST (SHOCKABLE RHYTHM)</span></p><p class=\"headingAnchor\" id=\"H4895863\"><span class=\"h2\">Adenosine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">Adenosine</a> is the drug of choice for uncomplicated supraventricular tachycardia (SVT) in children (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">Adenosine</a> interacts with Adenosine1 receptors on the surface of cardiac cells; the resulting effects include slowing of the sinus rate and an increase in the atrioventricular node conduction delay. These actions interrupt the reentrant circuit of tachycardias that require the atrioventricular node for reentry, which account for the great majority of cases of SVT in children. While adenosine is effective in terminating SVT associated with atrioventricular (AV) node reentry, AV reentry tachycardia associated with an accessory pathway, sinus node reentry, and automatic atrial tachycardia, it is <strong>not</strong> effective for atrial flutter, atrial fibrillation, atrial tachycardia or VT that is <strong>not</strong> caused by reentry at the AV node. (See <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H9\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'First-line therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indication and contraindications</strong> &ndash; <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">Adenosine</a> is the drug of choice for the acute medical conversion of SVT unresponsive to vagal maneuvers (<a href=\"image.htm?imageKey=EM%2F67438\" class=\"graphic graphic_algorithm graphicRef67438 \">algorithm 1</a> and <a href=\"image.htm?imageKey=PEDS%2F53559\" class=\"graphic graphic_table graphicRef53559 \">table 2</a> and <a href=\"image.htm?imageKey=EM%2F70842\" class=\"graphic graphic_waveform graphicRef70842 \">waveform 1</a>). However, in children with Wolff-Parkinson-White syndrome, adenosine administration for SVT can cause atrial fibrillation with progression to ventricular fibrillation. As a result, caution should be used when giving adenosine if WPW is a possible mechanism; emergency resuscitation equipment should be available and when possible, a pediatric cardiologist should be consulted before treatment. (See <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H8\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'Antiarrhythmic therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">Adenosine</a> is also contraindicated in patients with pre-existing second or third degree heart block or sinus node disease. (See <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H9\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'First-line therapy'</a>.)</p><p/><p class=\"bulletIndent1\">Although <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> is considered to be the drug of choice for conversion of uncomplicated SVT in children, there are some children with frequently recurrent or refractory SVT who are poorly responsive to adenosine. These patients commonly have impaired ventricular function or are recovering from surgery for congenital heart disease [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/40\" class=\"abstract_t\">40</a>]. <a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Procainamide</a> or <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> are suggested agents for such patients if they do not respond to adenosine. (See <a href=\"#H4895234\" class=\"local\">'Procainamide'</a> below and <a href=\"#H8196866\" class=\"local\">'Amiodarone'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration</strong> &ndash; The usual initial dose of <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> for SVT is 0.1 <span class=\"nowrap\">mg/kg</span> rapid IV push (maximum first dose 6 mg) followed immediately with a 5 mL saline flush to promote drug entry into the systemic circulation. Dosing is discussed in greater detail separately. (See <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H9\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'First-line therapy'</a>.)</p><p/><p class=\"bulletIndent1\">Because the elimination half-life of <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> is 10 seconds, it should be given in an intravenous line as close to the heart as possible. If adenosine is given too slowly or with an inadequate saline flush, then less of the drug may reach the heart and decrease efficacy. The use of two syringes (one with adenosine and the other with normal saline flush) connected to a T-connector or a stopcock is a useful way of ensuring rapid and effective drug delivery.</p><p/><p class=\"bulletIndent1\">A systematic review of five case series (232 infants and children) suggests that an <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> dose of 0.1 <span class=\"nowrap\">mg/kg</span> will successfully reverse SVT in 20 to 65 percent of patients [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/41\" class=\"abstract_t\">41</a>]. Subsequent doses may be increased by 0.1 <span class=\"nowrap\">mg/kg</span> to a maximum single dose of 0.3 <span class=\"nowrap\">mg/kg</span> (maximum total single dose 12 mg). In children &gt;50 kg, the initial adult dose of 6 mg should be given with subsequent doses being the maximum single dose of 12 mg. (See <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H9\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'First-line therapy'</a>.)</p><p/><p class=\"bulletIndent1\">The most common side effects reported after <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> administration are flushing, chest discomfort, nausea, and headache. Transient sinus bradycardia or heart block may occur, usually lasting between 10 and 40 seconds. Bronchospasm has been reported in patients with asthma who receive adenosine. (See <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H9\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'First-line therapy'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H8196866\"><span class=\"h2\">Amiodarone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">Amiodarone</a> may be used for the treatment of pulseless ventricular arrhythmias and is also potentially useful for supraventricular and stable ventricular arrhythmias (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">Amiodarone</a> is a class III antiarrhythmic agent that slows atrioventricular (AV) node conduction, prolongs the AV node refractory period and QT interval, and slows ventricular conduction (widens the QRS). These actions are mediated through effects on sodium, potassium, and calcium channels as well as blocking alpha- and beta-adrenergic receptors. (See <a href=\"topic.htm?path=clinical-uses-of-amiodarone#H27142119\" class=\"medical medical_review\">&quot;Clinical uses of amiodarone&quot;, section on 'Pharmacokinetics'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and contraindications</strong> &ndash; <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">Amiodarone</a> is effective in treating both ventricular and supraventricular arrhythmias that are resistant to other therapies.</p><p/><p class=\"bulletIndent1\">In children, <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> is suggested for the treatment of pulseless ventricular arrhythmias or stable ventricular tachycardia (VT) (<a href=\"image.htm?imageKey=EM%2F67438\" class=\"graphic graphic_algorithm graphicRef67438 \">algorithm 1</a>). Based upon the <a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>, amiodarone is <strong>not</strong> preferred over <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">lidocaine</a> for the treatment of shock-refractory ventricular fibrillation or pulseless ventricular tachycardia [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/42,43\" class=\"abstract_t\">42,43</a>].</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">Amiodarone</a> is also used for supraventricular tachycardia that is refractory to <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a>. However, <a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">procainamide</a> may be more effective in this situation. (See <a href=\"#H4895234\" class=\"local\">'Procainamide'</a> below and <a href=\"#H4895863\" class=\"local\">'Adenosine'</a> above and <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H4279881594\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'SVT refractory to adenosine'</a>.)</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">Amiodarone</a> should not be administered together with another drug that causes QT prolongation, such as <a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">procainamide</a>, without expert consultation [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. It is contraindicated in patients with congenital prolonged QT syndrome because it can exacerbate ventricular arrhythmias [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p class=\"bulletIndent1\">In a small pediatric case series of 40 children who did not respond to standard therapy, 80 percent had successful cessation of critical tachyarrhythmias (eg, atrial or ventricular tachyarrhythmias, junctional ectopic tachycardia) after receiving intravenous <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/45\" class=\"abstract_t\">45</a>]. Most of these patients developed these arrhythmias after cardiac surgery.</p><p/><p class=\"bulletIndent1\">However, in a multicenter observational study of inpatient treatment of pulseless ventricular tachycardia and ventricular fibrillation in 889 patients younger than 18 years of age, administration of <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> (171 patients; 82 who also received <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">lidocaine</a>) was <strong>not</strong> associated with return of spontaneous circulation (ROSC), 24 hour survival, or survival to discharge [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/46\" class=\"abstract_t\">46</a>]. Lidocaine administration (295 patients) was associated with significantly improved ROSC (adjusted odds ratio [OR] 2.0) and 24 hour survival (adjusted OR 1.7) but not survival to discharge. Thus, either amiodarone or lidocaine is appropriate medications for the initial treatment of ventricular arrhythmias in children.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration</strong> &ndash; <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">Amiodarone</a> may be given via rapid intravenous or intraosseous bolus in a dose of 5 <span class=\"nowrap\">mg/kg</span> (maximum single dose: 300 mg). The 5 <span class=\"nowrap\">mg/kg</span> dose may be repeated up to a maximum daily dose of 15 <span class=\"nowrap\">mg/kg</span> (maximum recommended daily dose 2.2 g) [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/47\" class=\"abstract_t\">47</a>]. Alternatively, based upon a small case series, a 10 <span class=\"nowrap\">mg/kg</span> per day continuous infusion appears safe and effective and may be started if there is a response to the initial bolus [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">Amiodarone</a> should <strong>not</strong> be administered through an endotracheal tube.</p><p/><p class=\"headingAnchor\" id=\"H4895234\"><span class=\"h2\">Procainamide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Procainamide</a> is a class IA antiarrhythmic that is an alternative to <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> for the treatment of supraventricular tachycardia (SVT) refractory to <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> or stable ventricular tachycardia (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; <a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Procainamide</a> is a sodium channel blocker that prolongs the refractory period of both the atria and ventricles and slows conduction velocity. Unlike <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a>, procainamide does not block reentry at the atrioventricular node and can be safely used in patients with Wolff-Parkinson-White syndrome. (See <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H4279881594\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'SVT refractory to adenosine'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and contraindications</strong> &ndash; <a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Procainamide</a> is suggested for the treatment SVT that is unresponsive to <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> or stable ventricular tachycardia (<a href=\"image.htm?imageKey=EM%2F67438\" class=\"graphic graphic_algorithm graphicRef67438 \">algorithm 1</a>). Procainamide may be more effective than <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> in patients with refractory supraventricular arrhythmias. As an example, in an observational study of 37 pediatric patients (24 with congenital heart disease), procainamide was significantly more effective than amiodarone in terminating refractory supraventricular tachycardia (50 versus 15 percent) without an observed difference in adverse effects [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/40\" class=\"abstract_t\">40</a>].</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Procainamide</a> should be <strong>avoided</strong> in patients who have received <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a>. It is contraindicated for patients with allergy to procainamide or related drugs (eg, procaine penicillin), heart block (eg, complete or second degree heart block), or torsades de pointes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration</strong> &ndash; The intravenous (IV) loading dose in children younger than one year of age is 7 to 10 <span class=\"nowrap\">mg/kg</span> given over 30 to 60 minutes. Children older than one year should receive a loading dose of 15 <span class=\"nowrap\">mg/kg</span>. The loading dose should be followed by a continuous IV infusion starting at 40 to 50 <span class=\"nowrap\">mcg/kg</span> per minute with measurement of plasma levels four hours after the loading dose. (See <a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children#H4279881594\" class=\"medical medical_review\">&quot;Management of supraventricular tachycardia in children&quot;, section on 'SVT refractory to adenosine'</a>.)</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">Procainamide</a> should be given by slow infusion to avoid heart block, negative inotropic effects and prolongation of the QT interval (which will predispose to torsade de pointes) [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p class=\"headingAnchor\" id=\"H6659945\"><span class=\"h2\">Lidocaine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lidocaine</a> may be used as an alternative to <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> for the treatment of pulseless ventricular arrhythmias (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lidocaine</a> is a class IB antiarrhythmic that blocks sodium channels in cardiac conductive tissue when they are in the inactivated state at the end of depolarization and during early repolarization. This action results in inhibition of electrical conduction and automaticity, particularly in ischemic tissue [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indication and contraindications</strong> &ndash; <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lidocaine</a> is suggested for the treatment of pulseless ventricular arrhythmias that are refractory to high quality cardiopulmonary resuscitation, defibrillation, and <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a>. Based upon the <a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>, <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> is <strong>not</strong> preferred over lidocaine for this indication.</p><p/><p class=\"bulletIndent1\">In one multicenter observational study of 889 children younger than 18 years of age with inpatient treatment of pulseless ventricular tachycardia and ventricular fibrillation, <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">lidocaine</a> administration (295 patients) was associated with improved return of spontaneous circulation and 24 hour survival, but not survival to discharge. Thus, lidocaine or <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a> are suggested for the treatment of shock-resistant ventricular arrhythmias. Further study is needed to the reproducibility of these results and whether or not they are generalizable to out-of-hospital settings. (See <a href=\"#H8196866\" class=\"local\">'Amiodarone'</a> above.)</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lidocaine</a> is contraindicated in patients with Wolff-Parkinson-White syndrome and those who are allergic to amide-type local anesthetics (<a href=\"image.htm?imageKey=ALLRG%2F57120\" class=\"graphic graphic_table graphicRef57120 \">table 3</a>). It may also cause seizures and myocardial and circulatory depression, especially in children with poor cardiac output and those with renal or liver failure [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=major-side-effects-of-class-i-antiarrhythmic-drugs#H16747176\" class=\"medical medical_review\">&quot;Major side effects of class I antiarrhythmic drugs&quot;, section on 'Lidocaine (intravenous)'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration</strong> &ndash; <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">Lidocaine</a> should be initially given as a single intravenous (IV) or intraosseous (IO) bolus dose of 1 <span class=\"nowrap\">mg/kg</span> followed by an infusion of 20 to 50 <span class=\"nowrap\">mcg/kg/minute</span>. If the start of the infusion will be delayed longer than 15 minutes, then a second IV or IO bolus dose of 1 <span class=\"nowrap\">mg/kg</span> is suggested.</p><p/><p class=\"bulletIndent1\">The initial bolus dose of <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">lidocaine</a> can be given endotracheally although IV or IO administration is strongly preferred. The suggested endotracheal dose is 2 to 3 <span class=\"nowrap\">mg/kg</span>. The technique for endotracheal medication administration is discussed below. Studies evaluating the absorption of lidocaine by the endotracheal route are lacking. (See <a href=\"#H23863422\" class=\"local\">'Endotracheal drug administration'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H8196901\"><span class=\"h2\">Magnesium sulfate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">Magnesium sulfate</a> is the primary agent recommended for the treatment of torsades de pointes (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; Magnesium is a crucial cofactor in the sodium-potassium-ATPase enzyme system. It stabilizes the motor membrane by reducing the sensitivity of the motor end plate to acetylcholine. A decreased intracellular magnesium level promotes myocardial excitability but, even in the absence of a low magnesium level, a bolus of IV magnesium will suppress ectopic ventricular beats. At high levels, magnesium acts as a calcium channel blocker and can produce bradycardia with atrioventricular block and cardiac arrest. (See <a href=\"topic.htm?path=symptoms-of-hypermagnesemia#H3\" class=\"medical medical_review\">&quot;Symptoms of hypermagnesemia&quot;, section on 'Cardiovascular effects'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and contraindications</strong> &ndash; <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">Magnesium sulfate</a> is indicated in the treatment of torsades de pointes (polymorphic VT with long QT interval) or documented hypomagnesemia. Patients with hypokalemia and arrhythmias frequently have associated hypomagnesemia. (See <a href=\"topic.htm?path=supportive-data-for-advanced-cardiac-life-support-in-adults-with-sudden-cardiac-arrest#H10\" class=\"medical medical_review\">&quot;Supportive data for advanced cardiac life support in adults with sudden cardiac arrest&quot;, section on 'Magnesium sulfate'</a> and <a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion#H3\" class=\"medical medical_review\">&quot;Clinical manifestations of magnesium depletion&quot;, section on 'Hypokalemia'</a>.)</p><p/><p class=\"bulletIndent1\">Patients who receive <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">magnesium sulfate</a> require monitoring of serum magnesium concentrations. Magnesium should be administered with caution to patients with myasthenia gravis or other neuromuscular disease and patients with renal impairment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration</strong> &ndash; For torsades de pointes, <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">magnesium sulfate</a> should be diluted in 5 percent dextrose (D5W) to a 20 percent solution or less and given as an intravenous or intraosseous infusion at a dose of 25 to 50 <span class=\"nowrap\">mg/kg</span> (maximum dose: 2 g). The rate of infusion depends upon the clinical situation:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with pulseless arrest &ndash; Infuse over one to two minutes.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Perfusing patients &ndash; Infuse over 15 minutes because rapid infusion is associated with hypotension and asystole.</p><p/><p class=\"headingAnchor\" id=\"H4897390\"><span class=\"h1\">LIMITED INDICATIONS</span></p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Atropine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">Atropine</a> is primarily indicated for vasovagal-induced bradycardia or the treatment of primary atrioventricular block (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>). &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">Atropine</a> is a parasympatholytic drug that increases heart rate by accelerating the sinus and atrial pacemaker and improving conduction through the AV node. Although the dominant cardiac response is tachycardia, the heart rate may decrease transiently when small doses are administered [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/50\" class=\"abstract_t\">50</a>]. This decrease is thought to occur because atropine, at low doses, blocks the M1 muscarinic postganglionic receptors that provide feedback inhibition for synaptic acetylcholine release [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/51\" class=\"abstract_t\">51</a>]; the resulting increase in acetylcholine inhibits spontaneous impulse generation in the SA node.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and contraindications</strong> &ndash; <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">Atropine</a> is recommended for children with bradycardia caused by increased vagal tone or primary atrioventricular block or unresponsive to oxygen, airway support, and administration of <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> (<a href=\"image.htm?imageKey=EM%2F52446\" class=\"graphic graphic_algorithm graphicRef52446 \">algorithm 2</a>).</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">Atropine</a> is no longer routinely recommended in children undergoing endotracheal intubation and is not recommended for pediatric patients with cardiac arrest (<a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>). However, it is suggested as a pre-treatment for rapid sequence intubation (RSI) in patients with septic or late stage hypovolemic shock, children &le;5 years of age receiving <a href=\"topic.htm?path=succinylcholine-suxamethonium-pediatric-drug-information\" class=\"drug drug_pediatric\">succinylcholine</a>, and children &gt;5 years of age requiring a second dose of succinylcholine. Furthermore, it is frequently used during RSI in infants &lt;1 year of age to counteract vagally-induced bradycardia. (See <a href=\"topic.htm?path=rapid-sequence-intubation-rsi-outside-the-operating-room-in-children-approach#H11\" class=\"medical medical_review\">&quot;Rapid sequence intubation (RSI) outside the operating room in children: Approach&quot;, section on 'Pretreatment'</a>.)</p><p/><p class=\"bulletIndent1\">Sinus tachycardia may occur after administration of <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> but it usually is well tolerated in children. The development of hypoxia-induced bradycardia may be masked if atropine is given to block vagal-induced bradycardia during intubation. In these cases, the use of pulse oximetry is recommended to monitor oxygenation. (See <a href=\"topic.htm?path=rapid-sequence-intubation-rsi-outside-the-operating-room-in-children-approach#H11\" class=\"medical medical_review\">&quot;Rapid sequence intubation (RSI) outside the operating room in children: Approach&quot;, section on 'Pretreatment'</a>.)</p><p/><p class=\"bulletIndent1\">Fixed and dilated pupils should <strong>not</strong> be attributed to <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> because atropine causes dilation of the pupils but does not eliminate the pupil constrictive response to light [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/52\" class=\"abstract_t\">52</a>].</p><p/><p class=\"bulletIndent1\">When not being used in a resuscitation situation, <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> is <strong>contraindicated</strong> in patients with obstructive gastrointestinal or genitourinary conditions (eg, surgical abdomen, paralytic ileus, posterior urethral valves), and myasthenia gravis (unless treating side effects of acetylcholinesterase inhibition) because it may exacerbate the underlying condition [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/53\" class=\"abstract_t\">53</a>]. Atropine may cause additional tachycardia in patients with thyrotoxicosis and mucous plugging in patients with asthma. It should also be used with caution in patients with hyperthermia and delirium because of its central anticholinergic effects. (See <a href=\"topic.htm?path=anticholinergic-poisoning\" class=\"medical medical_review\">&quot;Anticholinergic poisoning&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration</strong> &ndash; The dose of <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> varies depending on the route of administration. Although it can be given endotracheally, administration by the intravenous (IV) or the intraosseous route (IO) is preferred [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong><span class=\"nowrap\">IV/IO</strong></span> <strong>route</strong> &ndash; The recommended IV or IO dose of <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> is 0.02 <span class=\"nowrap\">mg/kg</span>. The maximum single dose is 1 mg. The dose may be repeated once, if needed [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. Higher doses probably are not routinely necessary because a total dose of 2 mg is sufficient to produce full vagal blockade in an adult [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/54\" class=\"abstract_t\">54</a>].</p><p/><p class=\"bulletIndent2\">Patients with poisoning from cholinesterase inhibiting agents may require much higher doses of <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> to dry bronchial secretions. (See <a href=\"topic.htm?path=organophosphate-and-carbamate-poisoning#H12\" class=\"medical medical_review\">&quot;Organophosphate and carbamate poisoning&quot;, section on 'Atropine'</a>.)</p><p/><p class=\"bulletIndent2\">A minimum parenteral dose of 0.1 mg has been suggested based upon a study that showed that very low doses of <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> (0.0036 <span class=\"nowrap\">mg/kg)</span> were associated with a mild slowing of heart rate [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/50\" class=\"abstract_t\">50</a>]. This low dose effect was most evident in school-aged children. However, in neonates who weigh less than 5 kg, this minimum dose can lead to anticholinergic toxicity [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/55,56\" class=\"abstract_t\">55,56</a>]. In the 2015 update, the American Heart Association Emergency Care Committee supports a weight-based dose of 0.02 <span class=\"nowrap\">mg/kg</span> with no minimum dose when atropine is given prior to endotracheal intubation [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/7,8,55\" class=\"abstract_t\">7,8,55</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Endotracheal route</strong> &ndash; Studies evaluating the absorption of <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> by the endotracheal route are lacking. The recommended dose for endotracheal administration is 0.04 to 0.06 <span class=\"nowrap\">mg/kg,</span> which may also be repeated once [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. The technique for endotracheal medication administration is provided below. (See <a href=\"#H23863422\" class=\"local\">'Endotracheal drug administration'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Sodium bicarbonate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The routine use of <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> is <strong>not</strong> recommended because of lack of convincing evidence of beneficial effects and potential adverse effects [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/15\" class=\"abstract_t\">15</a>].</p><p>A combined respiratory and metabolic acidosis develops during cardiopulmonary arrest. Hypoxia-induced anaerobic metabolism generates lactic acid, and ventilatory failure causes carbon dioxide retention. In addition, during shock or cardiac arrest, metabolic acid excretion is diminished because renal perfusion is inadequate. The severity of the acidosis worsens as the arrested state continues [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/57\" class=\"abstract_t\">57</a>].</p><p>The most effective means of correcting the acidosis in cardiac arrest is to provide adequate oxygenation, ventilation, and tissue perfusion. Because most pediatric cardiac arrests are caused by respiratory failure, support of ventilation through early intubation is the primary treatment, followed by support of the circulation with fluids and inotropic agents [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2,57\" class=\"abstract_t\">2,57</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">Sodium bicarbonate</a> increases blood pH by buffering excess blood hydrogen ion as long as the patient has adequate ventilation to excrete carbon dioxide.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and contraindications</strong> &ndash;<strong> </strong>The American Heart Association (AHA) recommends that <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> be considered only in children with prolonged cardiac arrest and documented severe metabolic acidosis who fail to respond to oxygenation, ventilation, fluids, and chest compressions combined with <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> in recommended doses [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/7,8,15\" class=\"abstract_t\">7,8,15</a>]. Sodium bicarbonate also may be considered when shock is associated with documented metabolic acidosis. (See <a href=\"topic.htm?path=systemic-inflammatory-response-syndrome-sirs-and-sepsis-in-children-definitions-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=hypovolemic-shock-in-children-initial-evaluation-and-management#H13\" class=\"medical medical_review\">&quot;Hypovolemic shock in children: Initial evaluation and management&quot;, section on 'Fluid resuscitation'</a>.)</p><p/><p class=\"bulletIndent1\">In children without cardiac arrest or shock, metabolic acidosis typically resolves with adequate volume replacement and ventilatory support. Additional indications for the administration of <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> include hyperkalemia, hypermagnesemia, tricyclic antidepressant overdose, or overdose from other sodium channel blocking agents [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2,15,58,59\" class=\"abstract_t\">2,15,58,59</a>]. (See <a href=\"topic.htm?path=treatment-and-prevention-of-hyperkalemia-in-adults\" class=\"medical medical_review\">&quot;Treatment and prevention of hyperkalemia in adults&quot;</a> and <a href=\"topic.htm?path=tricyclic-antidepressant-poisoning\" class=\"medical medical_review\">&quot;Tricyclic antidepressant poisoning&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">Sodium bicarbonate</a> administration should <strong>not</strong> be given to children with inadequate ventilation because inadequate respiratory excretion of carbon dioxide will lead to retention and worsening respiratory acidosis [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"bulletIndent1\">Excess administration of <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> during resuscitation has been associated with the following effects and should be avoided:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hypertonicity.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Worsening of intracellular acidosis with impairment of myocardial contractility. (See <a href=\"topic.htm?path=therapies-of-uncertain-benefit-in-basic-and-advanced-cardiac-life-support#H18\" class=\"medical medical_review\">&quot;Therapies of uncertain benefit in basic and advanced cardiac life support&quot;, section on 'Sodium bicarbonate therapy'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Extreme metabolic alkalosis with reduced oxygen delivery to the tissues, hypokalemia, and decreased plasma ionized calcium concentration. All of these adverse effects increase the risk for cardiac arrhythmias.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration </strong>&ndash; <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">Sodium bicarbonate</a> is administered by the intravenous (IV) or intraosseous (IO) route. It should <strong>not</strong> be given endotracheally because it is irritating to the airways, destroys lung surfactant, and can produce massive atelectasis [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/13\" class=\"abstract_t\">13</a>].</p><p/><p class=\"bulletIndent1\">The initial dose of <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> is 1 <span class=\"nowrap\">mEq/kg</span> (1 <span class=\"nowrap\">mL/kg</span> of 8.4 percent solution or 2 <span class=\"nowrap\">mL/kg</span> of 4.2 percent solution [recommended for children younger than six months of age]). The usual maximum single dose of sodium bicarbonate is 50 mEq for a child to 100 mEq for an adult patient.</p><p/><p class=\"bulletIndent1\">During prolonged arrests, subsequent doses of 0.5 <span class=\"nowrap\">mEq/kg</span> each may be given every 10 minutes by slow (one to two minutes) infusion or based upon blood gas analysis [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1,2\" class=\"abstract_t\">1,2</a>]. However, arterial blood gas analysis taken during cardiac arrest or severe shock may overestimate tissue and venous pH. Thus, central venous blood gas measurements, if possible, are advised to accurately assess acid-base status during resuscitation [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/60,61\" class=\"abstract_t\">60,61</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"nowrap\">IV/IO</span> tubing must be irrigated with normal saline before and after giving infusions of <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> to prevent inactivation of administered <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> or, in hypocalcemic or hyperkalemic patients, precipitation with <a href=\"topic.htm?path=calcium-chloride-pediatric-drug-information\" class=\"drug drug_pediatric\">calcium chloride</a>. (See <a href=\"#H6\" class=\"local\">'Epinephrine'</a> above and <a href=\"#H4895656\" class=\"local\">'Calcium'</a> below.)</p><p/><p class=\"bulletIndent1\">Repeated doses of <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> can also produce symptomatic hypernatremia and hyperosmolarity [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/62,63\" class=\"abstract_t\">62,63</a>]. Compared with plasma, the standard 8.4 percent sodium bicarbonate solution is hyperosmolar (2000 versus 289 <span class=\"nowrap\">mOsm/L)</span> [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>]. Use of hypertonic solutions in premature infants has been associated with an increased risk of developing periventricular-intraventricular hemorrhage [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/64\" class=\"abstract_t\">64</a>]. For this reason, a more dilute solution (4.2 percent) should be used in infants younger than six months of age [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2,13,57\" class=\"abstract_t\">2,13,57</a>].</p><p/><p class=\"bulletIndent1\">The administration of <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> may sclerose small veins and produces a chemical burn if extravasated into subcutaneous tissues [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/2\" class=\"abstract_t\">2</a>]. Transient vasodilation and hypotension can occur with rapid infusion [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/65\" class=\"abstract_t\">65</a>].</p><p/><p class=\"headingAnchor\" id=\"H4895656\"><span class=\"h2\">Calcium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Calcium has limited uses in pediatric resuscitation which include the treatment of hypocalcemia, hypermagnesemia, hyperkalemia, or calcium channel blocker overdose.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mechanisms</strong> &ndash; Calcium increases cardiac inotropy. Influx and efflux of calcium ions are important for the maintenance of normal conductivity and rhythm.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Indications and contraindications</strong> &ndash; Calcium has a very specific indication in cardiac arrests as emergency protection against the arrhythmogenic effects of hypocalcemia, hyperkalemia, hypermagnesemia, or calcium channel blocker overdose [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. It is otherwise not recommended for pediatric cardiopulmonary arrest because of an observed association with decreased survival and poor neurologic outcomes after pediatric arrests [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/66\" class=\"abstract_t\">66</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dose and administration </strong>&ndash; The optimum dose of calcium is based upon extrapolation from adult data and limited pediatric data. <a href=\"topic.htm?path=calcium-chloride-pediatric-drug-information\" class=\"drug drug_pediatric\">Calcium chloride</a> is preferred over <a href=\"topic.htm?path=calcium-gluconate-pediatric-drug-information\" class=\"drug drug_pediatric\">calcium gluconate</a> because it provides greater bioavailability of calcium but should only be given if central venous access is available because administration through a peripheral intravenous line is associated with skin necrosis and sloughing [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/67\" class=\"abstract_t\">67</a>]. Calcium gluconate is less irritating to the veins and may be administered by peripheral or central venous access.</p><p/><p class=\"bulletIndent1\">The recommended dose of elemental calcium is 5 to 7 <span class=\"nowrap\">mg/kg</span> [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"abstract_t\">1</a>]. Dosing in this range can be achieved by giving 0.2 <span class=\"nowrap\">mL/kg</span> of <a href=\"topic.htm?path=calcium-chloride-pediatric-drug-information\" class=\"drug drug_pediatric\">calcium chloride</a> 10 percent which provides 5.4 <span class=\"nowrap\">mg/kg</span> of <strong>elemental</strong> calcium or 0.6 <span class=\"nowrap\">mL/kg</span> of <a href=\"topic.htm?path=calcium-gluconate-pediatric-drug-information\" class=\"drug drug_pediatric\">calcium gluconate</a> 10 percent which provides 5.6 <span class=\"nowrap\">mg/kg</span> of <strong>elemental</strong> calcium. The maximum single dose is 540 mg of <strong>elemental</strong> calcium. Calcium chloride or calcium gluconate should be administered by slow intravenous push over 10 to 20 seconds in cardiac arrest and more slowly (eg, over 5 to 10 minutes) in perfusing patients.</p><p/><p class=\"bulletIndent1\">Rapid administration may cause bradycardia or asystole. If <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">sodium bicarbonate</a> is being given through the same intravenous line, the tubing must be thoroughly flushed before and after calcium administration. Otherwise an insoluble precipitate can form in the catheter lumen.</p><p/><p class=\"headingAnchor\" id=\"H23863422\"><span class=\"h1\">ENDOTRACHEAL DRUG ADMINISTRATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although lipid soluble drugs, such as <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">lidocaine</a>, <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a>, <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a>, and <a href=\"topic.htm?path=naloxone-pediatric-drug-information\" class=\"drug drug_pediatric\">naloxone</a> (&quot;LEAN&quot;) may be administered via an endotracheal tube (ETT), the intravascular route is always preferred [<a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Optimal drug dosing via endotracheal tube is unknown for many medications. Unpredictable drug absorption may lead to lower blood levels when compared with the same dose given intravascularly.</p><p>Several key actions are needed when giving drugs via an ETT:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increase the <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> dose 10-fold and the dose of other medications (<a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a>, <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">lidocaine</a>, <a href=\"topic.htm?path=naloxone-pediatric-drug-information\" class=\"drug drug_pediatric\">naloxone</a>) two- to threefold. (See <a href=\"#H6\" class=\"local\">'Epinephrine'</a> above and <a href=\"#H14\" class=\"local\">'Atropine'</a> above and <a href=\"topic.htm?path=opioid-intoxication-in-children-and-adolescents#H18254225\" class=\"medical medical_review\">&quot;Opioid intoxication in children and adolescents&quot;, section on 'Dosing and administration'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hold compressions during ETT administration.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dilute the medication in normal saline to a volume of 3 to 5 mL and instill into the endotracheal tube or beyond the tip of the endotracheal tube with a suction catheter.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Follow drug administration with 3 to 5 mL of normal saline.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Provide five positive pressure ventilations after instilling the drug.</p><p/><p class=\"headingAnchor\" id=\"H2385361018\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-basic-and-advanced-cardiac-life-support-in-children\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Basic and advanced cardiac life support in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5953323\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The primary drugs used in pediatric advanced life support (PALS), according to clinical presentation, are as follows (<a href=\"image.htm?imageKey=PEDS%2F70539\" class=\"graphic graphic_table graphicRef70539 \">table 1</a>) (see <a href=\"#H5952713\" class=\"local\">'Drug therapy by clinical condition'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Hypoxemia</strong> &ndash; Oxygen</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Hypoglycemia</strong> &ndash; Glucose</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Asystole or pulseless electrical activity</strong> &ndash; Oxygen, <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a> (<a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Pulseless with a shockable rhythm (ventricular fibrillation [VF], pulseless ventricular tachycardia [pVT], or torsades de pointes [TdP])</strong> &ndash; Oxygen, <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a>, and, for VF and pVT, <a href=\"topic.htm?path=lidocaine-pediatric-drug-information\" class=\"drug drug_pediatric\">lidocaine</a> or <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a>, and for TdP, <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">magnesium sulfate</a> as adjuncts to high quality cardiopulmonary resuscitation and defibrillation (<a href=\"https://eccguidelines.heart.org/wp-content/uploads/2015/10/PALS-Cardiac-Arrest-Algorithm.png&amp;token=piYIABGVAf9PLq9lwQ7iekpn+CgpjoUCjUamXk/D7vMFgAEITOoqAhSlAxnx1kxx3nlTpUaXUwwGWtqdqCpPYmvUyt29VZg1Gsj9Fy/L3pJ4wzYDR5B07w+kq1tr8epP&amp;TOPIC_ID=6386\" target=\"_blank\" class=\"external\">2015 Pediatric Cardiac Arrest Algorithm</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Uncomplicated supraventricular tachycardia (SVT) </strong>&ndash; Oxygen, <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a> (<a href=\"image.htm?imageKey=EM%2F67438\" class=\"graphic graphic_algorithm graphicRef67438 \">algorithm 1</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Possible ventricular tachycardia or aberrant SVT</strong> &ndash; Oxygen, <a href=\"topic.htm?path=adenosine-pediatric-drug-information\" class=\"drug drug_pediatric\">adenosine</a>, <a href=\"topic.htm?path=amiodarone-pediatric-drug-information\" class=\"drug drug_pediatric\">amiodarone</a>, <a href=\"topic.htm?path=procainamide-pediatric-drug-information\" class=\"drug drug_pediatric\">procainamide</a> (<a href=\"image.htm?imageKey=EM%2F67438\" class=\"graphic graphic_algorithm graphicRef67438 \">algorithm 1</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Hypomagnesemia or TdP</strong> &ndash; <a href=\"topic.htm?path=magnesium-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">Magnesium sulfate</a></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Bradycardia</strong> &ndash; Oxygen, <a href=\"topic.htm?path=epinephrine-adrenaline-pediatric-drug-information\" class=\"drug drug_pediatric\">epinephrine</a>, <a href=\"topic.htm?path=atropine-pediatric-drug-information\" class=\"drug drug_pediatric\">atropine</a> (<a href=\"image.htm?imageKey=EM%2F52446\" class=\"graphic graphic_algorithm graphicRef52446 \">algorithm 2</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Severe metabolic acidosis associated with prolonged cardiac arrest or shock</strong> &ndash; <a href=\"topic.htm?path=sodium-bicarbonate-pediatric-drug-information\" class=\"drug drug_pediatric\">Sodium bicarbonate</a></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Hypocalcemia, hypermagnesemia, hyperkalemia or calcium channel blocker overdose</strong> &ndash; <a href=\"topic.htm?path=calcium-chloride-pediatric-drug-information\" class=\"drug drug_pediatric\">Calcium chloride</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition to these agents, all critically ill children should receive supplemental oxygen. (See <a href=\"#H2\" class=\"local\">'Oxygen'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The use of <a href=\"topic.htm?path=naloxone-pediatric-drug-information\" class=\"drug drug_pediatric\">naloxone</a> for children with suspected opioid intoxication and clinical findings of coma, depressed respirations, <span class=\"nowrap\">and/or</span> miosis is discussed separately. (See <a href=\"topic.htm?path=opioid-intoxication-in-children-and-adolescents#H27\" class=\"medical medical_review\">&quot;Opioid intoxication in children and adolescents&quot;, section on 'Naloxone'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In children undergoing pediatric advanced life support (PALS), medications are of secondary importance to the prompt treatment of hypoxemia and respiratory impairment, initiation of high quality compressions during cardiopulmonary resuscitation, and, in pulseless patients with ventricular arrhythmias, early defibrillation. (See <a href=\"#H5952713\" class=\"local\">'Drug therapy by clinical condition'</a> above and <a href=\"topic.htm?path=basic-airway-management-in-children\" class=\"medical medical_review\">&quot;Basic airway management in children&quot;</a> and <a href=\"topic.htm?path=pediatric-basic-life-support-for-health-care-providers\" class=\"medical medical_review\">&quot;Pediatric basic life support for health care providers&quot;</a> and <a href=\"topic.htm?path=defibrillation-and-cardioversion-in-children-including-automated-external-defibrillation\" class=\"medical medical_review\">&quot;Defibrillation and cardioversion in children (including automated external defibrillation)&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2294319993\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Pamela Bailey, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/1\" class=\"nounderline abstract_t\">Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.</a></li><li class=\"breakAll\">Pediatric Advanced Life Support Provider Manual, Samson RA, Schexnayder SM, Hazinski MF (Eds), American  Heart Association, Dallas 2012. p.209.</li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/3\" class=\"nounderline abstract_t\">Michaud LJ, Rivara FP, Longstreth WT Jr, Grady MS. Elevated initial blood glucose levels and poor outcome following severe brain injuries in children. J Trauma 1991; 31:1356.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/4\" class=\"nounderline abstract_t\">D'Alecy LG, Lundy EF, Barton KJ, Zelenock GB. Dextrose containing intravenous fluid impairs outcome and increases death after eight minutes of cardiac arrest and resuscitation in dogs. Surgery 1986; 100:505.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/5\" class=\"nounderline abstract_t\">Nakakimura K, Fleischer JE, Drummond JC, et al. Glucose administration before cardiac arrest worsens neurologic outcome in cats. Anesthesiology 1990; 72:1005.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/6\" class=\"nounderline abstract_t\">Voorhies TM, Rawlinson D, Vannucci RC. Glucose and perinatal hypoxic-ischemic brain damage in the rat. Neurology 1986; 36:1115.</a></li><li class=\"breakAll\">American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care - Part 11: Pediatric Basic Life Support and Cardiopulmonary Resuscitation Quality. ECCguidelines.heart.org (Accessed on October 15, 2015).</li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/8\" class=\"nounderline abstract_t\">Atkins DL, Berger S, Duff JP, et al. Part 11: Pediatric Basic Life Support and Cardiopulmonary Resuscitation Quality: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132:S519.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/9\" class=\"nounderline abstract_t\">Paradis NA, Koscove EM. Epinephrine in cardiac arrest: a critical review. Ann Emerg Med 1990; 19:1288.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/10\" class=\"nounderline abstract_t\">Goetting MG, Paradis NA. High-dose epinephrine improves outcome from pediatric cardiac arrest. Ann Emerg Med 1991; 20:22.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/11\" class=\"nounderline abstract_t\">Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990; 263:1106.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/12\" class=\"nounderline abstract_t\">Michael JR, Guerci AD, Koehler RC, et al. Mechanisms by which epinephrine augments cerebral and myocardial perfusion during cardiopulmonary resuscitation in dogs. Circulation 1984; 69:822.</a></li><li class=\"breakAll\">Ludwig S, Lavelle JM. Resuscitation-pediatric basic and advanced life support. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.3.</li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/14\" class=\"nounderline abstract_t\">Otto CW, Yakaitis RW, Blitt CD. Mechanism of action of epinephrine in resuscitation from asphyxial arrest. Crit Care Med 1981; 9:321.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/15\" class=\"nounderline abstract_t\">Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.</a></li><li class=\"breakAll\">US Food &amp; Drug Administration. Important Labeling Changes to Critical Care Medications. https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm562565.htm (Accessed on October 10, 2017).</li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/17\" class=\"nounderline abstract_t\">Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VII. Neonatal resuscitation. JAMA 1992; 268:2276.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/18\" class=\"nounderline abstract_t\">Orlowski JP, Gallagher JM, Porembka DT. Endotracheal epinephrine is unreliable. Resuscitation 1990; 19:103.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/19\" class=\"nounderline abstract_t\">Zaritsky A. Pediatric resuscitation pharmacology. Members of the Medications in Pediatric Resuscitation Panel. Ann Emerg Med 1993; 22:445.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/20\" class=\"nounderline abstract_t\">Brown CG, Werman HA, Davis EA, et al. Comparative effect of graded doses of epinephrine on regional brain blood flow during CPR in a swine model. Ann Emerg Med 1986; 15:1138.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/21\" class=\"nounderline abstract_t\">Brown CG, Werman HA, Davis EA, et al. The effects of graded doses of epinephrine on regional myocardial blood flow during cardiopulmonary resuscitation in swine. Circulation 1987; 75:491.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/22\" class=\"nounderline abstract_t\">Gonzalez ER, Ornato JP, Garnett AR, et al. Dose-dependent vasopressor response to epinephrine during CPR in human beings. Ann Emerg Med 1989; 18:920.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/23\" class=\"nounderline abstract_t\">Goetting MG, Paradis NA. High dose epinephrine in refractory pediatric cardiac arrest. Crit Care Med 1989; 17:1258.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/24\" class=\"nounderline abstract_t\">Dieckmann RA, Vardis R. High-dose epinephrine in pediatric out-of-hospital cardiopulmonary arrest. Pediatrics 1995; 95:901.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/25\" class=\"nounderline abstract_t\">Brown CG, Martin DR, Pepe PE, et al. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. N Engl J Med 1992; 327:1051.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/26\" class=\"nounderline abstract_t\">Stiell IG, Hebert PC, Weitzman BN, et al. High-dose epinephrine in adult cardiac arrest. N Engl J Med 1992; 327:1045.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/27\" class=\"nounderline abstract_t\">Berg RA, Otto CW, Kern KB, et al. A randomized, blinded trial of high-dose epinephrine versus standard-dose epinephrine in a swine model of pediatric asphyxial cardiac arrest. Crit Care Med 1996; 24:1695.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/28\" class=\"nounderline abstract_t\">Carpenter TC, Stenmark KR. High-dose epinephrine is not superior to standard-dose epinephrine in pediatric in-hospital cardiopulmonary arrest. Pediatrics 1997; 99:403.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/29\" class=\"nounderline abstract_t\">Perondi MB, Reis AG, Paiva EF, et al. A comparison of high-dose and standard-dose epinephrine in children with cardiac arrest. N Engl J Med 2004; 350:1722.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/30\" class=\"nounderline abstract_t\">American Heart Association. Management of cardiac arrest. Circulation 2005; 112:IV.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/31\" class=\"nounderline abstract_t\">Haft JI. Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis 1974; 17:73.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/32\" class=\"nounderline abstract_t\">Rivers EP, Wortsman J, Rady MY, et al. The effect of the total cumulative epinephrine dose administered during human CPR on hemodynamic, oxygen transport, and utilization variables in the postresuscitation period. Chest 1994; 106:1499.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/33\" class=\"nounderline abstract_t\">Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VI. Pediatric advanced life support. JAMA 1992; 268:2262.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/34\" class=\"nounderline abstract_t\">Stroumpoulis K, Xanthos T, Rokas G, et al. Vasopressin and epinephrine in the treatment of cardiac arrest: an experimental study. Crit Care 2008; 12:R40.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/35\" class=\"nounderline abstract_t\">Jing XL, Li X, Li H, et al. Vasopressin and epinephrine versus epinephrine in management of patients with cardiac arrest: a meta-analysis. Signa Vitae 2010; 5:20.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/36\" class=\"nounderline abstract_t\">Mann K, Berg RA, Nadkarni V. Beneficial effects of vasopressin in prolonged pediatric cardiac arrest: a case series. Resuscitation 2002; 52:149.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/37\" class=\"nounderline abstract_t\">Gil-Ant&oacute;n J, L&oacute;pez-Herce J, Morteruel E, et al. Pediatric cardiac arrest refractory to advanced life support: is there a role for terlipressin? Pediatr Crit Care Med 2010; 11:139.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/38\" class=\"nounderline abstract_t\">Yilidzda&#351; D, Horoz OO, Erdem S. Beneficial effects of terlipressin in pediatric cardiac arrest. Pediatr Emerg Care 2011; 27:865.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/39\" class=\"nounderline abstract_t\">Duncan JM, Meaney P, Simpson P, et al. Vasopressin for in-hospital pediatric cardiac arrest: results from the American Heart Association National Registry of Cardiopulmonary Resuscitation. Pediatr Crit Care Med 2009; 10:191.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/40\" class=\"nounderline abstract_t\">Chang PM, Silka MJ, Moromisato DY, Bar-Cohen Y. Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients. Circ Arrhythm Electrophysiol 2010; 3:134.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/41\" class=\"nounderline abstract_t\">Quail MA, Till J. Question 3 Does a higher initial dose of adenosine improve cardioversion rates in supraventricular tachycardia? Arch Dis Child 2012; 97:177.</a></li><li class=\"breakAll\">American Heart Association. Web-based Integrated Guidelines for Cardiopulmonary and Emergency Cardiovascular Care - Part 12. Pediatric advanced life support. https://eccguidelines.heart.org/index.php/circulation/cpr-ecc-guidelines-2/part-12-pediatric-advanced-life-support/ (Accessed on November 10, 2015).</li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/43\" class=\"nounderline abstract_t\">de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132:S526.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/44\" class=\"nounderline abstract_t\">Fishberger SB, Hannan RL, Welch EM, Rossi AF. Amiodarone for pediatric resuscitation: a word of caution. Pediatr Cardiol 2009; 30:1006.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/45\" class=\"nounderline abstract_t\">Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/46\" class=\"nounderline abstract_t\">Valdes SO, Donoghue AJ, Hoyme DB, et al. Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. Resuscitation 2014; 85:381.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/47\" class=\"nounderline abstract_t\">Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112:3470.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/48\" class=\"nounderline abstract_t\">Ramusovic S, L&auml;er S, Meibohm B, et al. Pharmacokinetics of intravenous amiodarone in children. Arch Dis Child 2013; 98:989.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/49\" class=\"nounderline abstract_t\">Luedtke SA, Kuhn RJ, McCaffrey FM. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. Ann Pharmacother 1997; 31:1347.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/50\" class=\"nounderline abstract_t\">Dauchot P, Gravenstein JS. Effects of atropine on the electrocardiogram in different age groups. Clin Pharmacol Ther 1971; 12:274.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/51\" class=\"nounderline abstract_t\">Todd GL, Baroldi G, Pieper GM, et al. Experimental catecholamine-induced myocardial necrosis. I. Morphology, quantification and regional distribution of acute contraction band lesions. J Mol Cell Cardiol 1985; 17:317.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/52\" class=\"nounderline abstract_t\">Goetting MG, Contreras E. Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils. Ann Emerg Med 1991; 20:55.</a></li><li class=\"breakAll\">Atropine. In: Martindale: The Complete Drug Reference, Sweetman SC (Ed), Pharmaceutical Press, London. Electronic version 2011.</li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/54\" class=\"nounderline abstract_t\">O'Rourke GW, Greene NM. Autonomic blockade and the resting heart rate in man. Am Heart J 1970; 80:469.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/55\" class=\"nounderline abstract_t\">Barrington KJ. The myth of a minimum dose for atropine. Pediatrics 2011; 127:783.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/56\" class=\"nounderline abstract_t\">Barrington KJ, Byrne PJ. Premedication for neonatal intubation. Am J Perinatol 1998; 15:213.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/57\" class=\"nounderline abstract_t\">Ushay HM, Notterman DA. Pharmacology of pediatric resuscitation. Pediatr Clin North Am 1997; 44:207.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/58\" class=\"nounderline abstract_t\">Ettinger PO, Regan TJ, Oldewurtel HA. Hyperkalemia, cardiac conduction, and the electrocardiogram: a review. Am Heart J 1974; 88:360.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/59\" class=\"nounderline abstract_t\">Hoffman JR, Votey SR, Bayer M, Silver L. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J Emerg Med 1993; 11:336.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/60\" class=\"nounderline abstract_t\">Weil MH, Rackow EC, Trevino R, et al. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med 1986; 315:153.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/61\" class=\"nounderline abstract_t\">Steedman DJ, Robertson CE. Acid base changes in arterial and central venous blood during cardiopulmonary resuscitation. Arch Emerg Med 1992; 9:169.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/62\" class=\"nounderline abstract_t\">M&aacute;ttar JA, Weil MH, Shubin H, Stein L. Cardiac arrest in the critically ill. II. Hyperosmolal states following cardiac arrest. Am J Med 1974; 56:162.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/63\" class=\"nounderline abstract_t\">Aufderheide TP, Martin DR, Olson DW, et al. Prehospital bicarbonate use in cardiac arrest: a 3-year experience. Am J Emerg Med 1992; 10:4.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/64\" class=\"nounderline abstract_t\">Howell JH. Sodium bicarbonate in the perinatal setting--revisited. Clin Perinatol 1987; 14:807.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/65\" class=\"nounderline abstract_t\">Cot&eacute; CJ, Greenhow DE, Marshall BE. The hypotensive response to rapid intravenous administration of hypertonic solutions in man and in the rabbit. Anesthesiology 1979; 50:30.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/66\" class=\"nounderline abstract_t\">Srinivasan V, Morris MC, Helfaer MA, et al. Calcium use during in-hospital pediatric cardiopulmonary resuscitation: a report from the National Registry of Cardiopulmonary Resuscitation. Pediatrics 2008; 121:e1144.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-drugs-in-pediatric-resuscitation/abstract/67\" class=\"nounderline abstract_t\">Broner CW, Stidham GL, Westenkirchner DF, Watson DC. A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children. J Pediatr 1990; 117:986.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6386 Version 24.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H5953323\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H5952713\" id=\"outline-link-H5952713\">DRUG THERAPY BY CLINICAL CONDITION</a></li><li><a href=\"#H4897046\" id=\"outline-link-H4897046\">SUBSTRATE DELIVERY</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">Oxygen</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Glucose (dextrose)</a></li></ul></li><li><a href=\"#H4897086\" id=\"outline-link-H4897086\">CARDIAC ARREST (ASYSTOLE OR PULSELESS ELECTRICAL ACTIVITY)</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Epinephrine</a></li></ul></li><li><a href=\"#H4897154\" id=\"outline-link-H4897154\">TACHYARRHYTHMIAS AND CARDIAC ARREST (SHOCKABLE RHYTHM)</a><ul><li><a href=\"#H4895863\" id=\"outline-link-H4895863\">Adenosine</a></li><li><a href=\"#H8196866\" id=\"outline-link-H8196866\">Amiodarone</a></li><li><a href=\"#H4895234\" id=\"outline-link-H4895234\">Procainamide</a></li><li><a href=\"#H6659945\" id=\"outline-link-H6659945\">Lidocaine</a></li><li><a href=\"#H8196901\" id=\"outline-link-H8196901\">Magnesium sulfate</a></li></ul></li><li><a href=\"#H4897390\" id=\"outline-link-H4897390\">LIMITED INDICATIONS</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Atropine</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Sodium bicarbonate</a></li><li><a href=\"#H4895656\" id=\"outline-link-H4895656\">Calcium</a></li></ul></li><li><a href=\"#H23863422\" id=\"outline-link-H23863422\">ENDOTRACHEAL DRUG ADMINISTRATION</a></li><li><a href=\"#H2385361018\" id=\"outline-link-H2385361018\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H5953323\" id=\"outline-link-H5953323\">SUMMARY</a></li><li><a href=\"#H2294319993\" id=\"outline-link-H2294319993\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"EM/6386|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=EM/67438\" class=\"graphic graphic_algorithm\">- Pediatric tachycardia algorithm</a></li><li><a href=\"image.htm?imageKey=EM/52446\" class=\"graphic graphic_algorithm\">- Pediatric bradycardia algorithm</a></li></ul></li><li><div id=\"EM/6386|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/70539\" class=\"graphic graphic_table\">- Doses pediatric resuscitation</a></li><li><a href=\"image.htm?imageKey=PEDS/53559\" class=\"graphic graphic_table\">- Pediatric supraventricular tachycardia rapid overview</a></li><li><a href=\"image.htm?imageKey=ALLRG/57120\" class=\"graphic graphic_table\">- Classification of local anesthetics</a></li></ul></li><li><div id=\"EM/6386|Waveform\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"WAVEFORMS\">WAVEFORMS</a></div><ul><li><a href=\"image.htm?imageKey=EM/70842\" class=\"graphic graphic_waveform\">- Conversion of supraventricular tachycardia with adenosine</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anticholinergic-poisoning\" class=\"medical medical_review\">Anticholinergic poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-hypoglycemia-in-infants-and-children\" class=\"medical medical_review\">Approach to hypoglycemia in infants and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=basic-airway-management-in-children\" class=\"medical medical_review\">Basic airway management in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-magnesium-depletion\" class=\"medical medical_review\">Clinical manifestations of magnesium depletion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-uses-of-amiodarone\" class=\"medical medical_review\">Clinical uses of amiodarone</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=continuous-oxygen-delivery-systems-for-infants-children-and-adults\" class=\"medical medical_review\">Continuous oxygen delivery systems for infants, children, and adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=defibrillation-and-cardioversion-in-children-including-automated-external-defibrillation\" class=\"medical medical_review\">Defibrillation and cardioversion in children (including automated external defibrillation)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypovolemic-shock-in-children-initial-evaluation-and-management\" class=\"medical medical_review\">Hypovolemic shock in children: Initial evaluation and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-class-i-antiarrhythmic-drugs\" class=\"medical medical_review\">Major side effects of class I antiarrhythmic drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-supraventricular-tachycardia-in-children\" class=\"medical medical_review\">Management of supraventricular tachycardia in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-resuscitation-in-the-delivery-room\" class=\"medical medical_review\">Neonatal resuscitation in the delivery room</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=opioid-intoxication-in-children-and-adolescents\" class=\"medical medical_review\">Opioid intoxication in children and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=organophosphate-and-carbamate-poisoning\" class=\"medical medical_review\">Organophosphate and carbamate poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oxygen-toxicity\" class=\"medical medical_review\">Oxygen toxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pediatric-advanced-life-support-pals\" class=\"medical medical_review\">Pediatric advanced life support (PALS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pediatric-basic-life-support-for-health-care-providers\" class=\"medical medical_review\">Pediatric basic life support for health care providers</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-sequence-intubation-rsi-outside-the-operating-room-in-children-approach\" class=\"medical medical_review\">Rapid sequence intubation (RSI) outside the operating room in children: Approach</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-basic-and-advanced-cardiac-life-support-in-children\" class=\"medical medical_society_guidelines\">Society guideline links: Basic and advanced cardiac life support in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sulfonylurea-agent-poisoning\" class=\"medical medical_review\">Sulfonylurea agent poisoning</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=supportive-data-for-advanced-cardiac-life-support-in-adults-with-sudden-cardiac-arrest\" class=\"medical medical_review\">Supportive data for advanced cardiac life support in adults with sudden cardiac arrest</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=symptoms-of-hypermagnesemia\" class=\"medical medical_review\">Symptoms of hypermagnesemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-inflammatory-response-syndrome-sirs-and-sepsis-in-children-definitions-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapies-of-uncertain-benefit-in-basic-and-advanced-cardiac-life-support\" class=\"medical medical_review\">Therapies of uncertain benefit in basic and advanced cardiac life support</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-hyperkalemia-in-adults\" class=\"medical medical_review\">Treatment and prevention of hyperkalemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tricyclic-antidepressant-poisoning\" class=\"medical medical_review\">Tricyclic antidepressant poisoning</a></li></ul></div></div>","javascript":null}